UNITED STATES SECURITIES AND EXCHANGE COMMISSION ~~Washington, D.C. 20549~~

Washington, DC 20549

FORM 8-K

CURRENT REPORT ~~Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934~~

~~Date~~Pursuant ofto ~~Report~~Section 13 or 15(~~Date~~d) of ~~earliest~~the Securities ~~event~~Exchange ~~reported):~~Act ~~June~~of ~~10, 2025~~ 1934

Date of Report (Date of earliest event reported): July 3, 2025

ANAVEX LIFE SCIENCES CORP.

(Exact name of registrant as specified in its charter)

Nevada	001-37606	98-0608404
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No.)

630 5th Avenue~~, 20th Floor, New York, NY USA 10111 (Address of principal executive offices) (Zip Code)~~

20th Floor

New York, NY 10111

(Address of principal executive offices) (Zip Code)

1-844-689-3939

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ~~(see General Instruction A.2. below)~~:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading ~~symbol(s)~~Symbol		Name of ~~each~~Each ~~exchange~~Exchange on ~~which~~Which ~~registered~~Registered
Common Stock, par value $0.001 per share		AVXL		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On ~~June~~July 103, 2025 and effective July 5, 2025, Anavex Life Sciences Corp. ~~(the~~, ~~“Company”)~~a ~~held~~Nevada ~~its~~corporation ~~Annual Meeting of Stockholders~~ (the “~~Annual Meeting~~Company”)~~. At the Annual Meeting~~, ~~stockholders~~ ~~approved~~entered aninto ~~amendment (~~the “Fourth Amendment”) to Employment ~~the~~Agreement ~~Company’s 2022 Omnibus Incentive Plan~~ (the “~~Plan~~Missling Amendment”) to ~~(i) increase the number of shares authorized for issuance thereunder by 4,000,000 shares (ii) establish a minimum vesting period of one year for all awards granted under the Plan,~~ with ~~exceptions~~Christopher ~~permitted only with respect to (a) substituted awards~~Missling, ~~(b) shares delivered~~ ~~in lieu of fully-vested cash awards~~PhD, ~~(c) acceleration of vesting~~ in ~~the~~his ~~event~~continuing ofcapacity aas ~~change~~Chief inExecutive ~~control~~Officer ~~or death or disability~~ of the ~~participant and~~Company. ~~(d)~~The ~~with~~Missling ~~respect~~Amendment toamends ~~any other awards covering 5% or fewer of~~ the ~~total~~Employment ~~number~~Agreement ofby ~~shares authorized under the Plan;~~ and ~~(iii) prohibit~~ ~~liberal~~between ~~share recycling by prohibiting (a)~~ the ~~re-use~~Company ~~of shares withheld or delivered to satisfy the exercise price of a stock option or stock appreciation right or other applicable purchase price of an award or to satisfy tax withholding requirements~~ and ~~(b)~~Dr. ~~“net share~~Missling, ~~counting”~~dated ~~upon~~June ~~the~~27, ~~exercise~~2013, ofas ~~stock~~most ~~options~~recently oramended ~~stock~~by ~~appreciation rights. The Board of Directors of~~ the ~~Company~~Third ~~previously approved the~~ Amendment to ~~Equity~~Employment ~~Incentive~~Agreement ~~Plan on~~ dated April 177, ~~2025~~2022 (as amended, ~~subject~~the to“Missling ~~stockholder~~Employment ~~approval~~Agreement”).

AThe ~~summary~~Missling ~~description~~Amendment ofis made to extend the ~~terms~~term of the ~~Amendment is~~Missling ~~set~~Employment ~~forth~~Agreement inthrough ~~the~~July ~~Company’s~~5, ~~definitive~~2028, ~~proxy~~unless ~~statement~~earlier onterminated ~~Schedule~~as ~~14A~~provided ~~filed~~in ~~with~~ the ~~Securities~~Missling ~~and~~Amendment. Pursuant ~~Exchange~~to ~~Commission~~the onterms ~~April 25,~~of ~~2025 (~~the ~~“Proxy~~Missling ~~Statement”)~~Amendment, ~~under~~beginning ~~the~~July ~~section~~5, of2025, ~~the~~Dr. ~~Proxy~~Missling ~~Statement~~shall ~~entitled~~receive ~~“Proposal~~an 3annual –base ~~Approval~~ salary of ~~Amendment~~$800,000 and is eligible to ~~Anavex~~earn ~~Life~~an ~~Sciences~~annual ~~Corp.~~cash ~~2022~~target ~~Omnibus~~bonus ~~Incentive~~for ~~Plan,”~~each ~~which~~whole isor ~~qualified~~partial bycalendar ~~the~~year ~~full~~of ~~text~~twenty percent of ~~the~~his ~~Amendment,~~base asalary and an ~~copy~~annual ofequity ~~which~~grant isin ~~attached~~an ~~hereto~~amount asto ~~Exhibit~~be ~~10.1~~determined ~~and~~by ~~incorporated~~the ~~herein~~compensation bycommittee ~~reference~~of the Company’s board of directors.

~~Item~~Additionally, ~~5.07~~effective ~~Submission~~July of3, 2025, ~~Matters~~the Company entered into the Third Amendment to aEmployment ~~Vote~~Agreement (the “Boenisch Amendment”) with Sandra Boenisch, in her continuing capacity as Principal Financial Officer of ~~Security~~the ~~Holders~~Company. The Boenisch Amendment amends the Amended and Restated Employment Agreement by and between the Company and the PFO dated October 4, 2017, as most recently amended by the Second Amendment to Employment Agreement dated February 28, 2022 (as amended, the “Boenisch Employment Agreement”).

AtThe Boenisch Amendment provides that the ~~Annual~~term ~~Meeting~~of onthe ~~June~~Boenisch ~~10,~~Employment ~~2025~~Agreement shall continue indefinitely, aunless ~~total~~terminated ofas provided in the Boenisch Amendment. ~~51,872,393~~Pursuant ~~shares~~to the terms of the ~~Company’s~~Boenisch ~~Common~~Amendment, ~~Stock~~Ms. ~~were~~Boenisch ~~present~~shall orreceive ~~represented~~an byannual ~~proxy~~base salary of $279,840 ~~representing~~Canadian ~~approximately~~Dollars ~~60.8%~~and is eligible to earn an annual cash target bonus for each calendar year of ~~the~~twenty ~~outstanding~~percent of her base salary. The Boenisch Amendment also ~~Common~~amended ~~Stock~~the astermination provisions of ~~April~~the ~~21,~~Boenisch ~~2025~~Employment Agreement, including to increase the ~~record~~amount ~~date~~of severance owed to Ms. Boenisch if she is terminated without cause from six (6) months to twelve (12) months of her base salary, and provides for ~~the~~additional ~~Annual~~employment related ~~Meeting~~benefits for Ms. Boenisch.

AtThe summary of the ~~Annual~~Missling ~~Meeting,~~Amendment and ~~three~~the ~~(3)~~Boenisch ~~proposals~~Amendment ~~were~~provided ~~submitted for~~herein ais ~~vote~~qualified ofin their entirety by the ~~Company’s~~terms ~~stockholders~~of such agreement, which are fully set forth and attached ~~the~~hereto ~~related~~as ~~results~~Exhibits 10.1 and 10.2, respectively, and which are asincorporated ~~follows:~~by reference herein.

~~Proposal~~Item No9.01 1:Financial ~~The~~Statements ~~election of Christopher Missling, PhD, Jiong Ma, PhD, Claus van der Velden, PhD, Athanasios Skarpelos, Steffen Thomas, PhD~~ and ~~Peter Donhauser, D~~Exhibits.O. for terms until the next succeeding annual meeting of stockholders or until such directors’ successor shall have been duly elected and qualified. The stockholders holding a majority of the Common Stock having voting power present in person or represented by proxy elected the six (6) directors by the following votes:

Name	For		Against		Abstain		Broker Non-Votes
Christopher Missling, PhD		20,820,793		1,507,135		162,073		29,382,392
Jiong Ma, PhD		21,522,986		814,833		152,182		29,382,392
Claus van der Velden, PhD		19,544,463		2,573,335		372,201		29,382,394
Athanasios Skarpelos		21,354,077		997,680		138,244		29,382,392
Steffen Thomas, PhD		20,655,433		1,520,593		313,973		29,382,394
Peter Donhauser, D.O.		20,707,130		1,450,145		332,724		29,382,294

(d) Exhibits.

Proposal No. 2: The stockholders holding a majority of the Common Stock having voting power present in person or represented by proxy ratified Grant Thornton LLP as the Company’s independent registered accounting firm by the following votes:

EXHIBIT NO.	DESCRIPTION	LOCATION
10.1	Fourth Amendment to Employment Agreement by and between Anavex Life Sciences Corp. and Christopher Missling, PhD, dated July 3, 2025	Filed herewith
10.2	Third Amendment to Employment Agreement by and between Anavex Life Sciences Corp. and Sandra Boenisch, dated July 3, 2025	Filed herewith
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

For				Against				Abstain
	49,615,076				1,851,116				406,201

SIGNATURES

~~Proposal~~Pursuant ~~No.~~to 3:the ~~The~~requirements ~~approval~~ of the anSecurities ~~amendment to~~Exchange Act of 1934, the ~~Company’s~~registrant ~~2022~~has ~~Omnibus~~duly ~~Incentive~~caused ~~Plan.~~this ~~The~~report ~~stockholders~~to ~~approved~~be ~~the~~signed ~~proposal~~on its behalf by the ~~following~~undersigned ~~votes:~~hereunto duly authorized.

For				Against				Abstain				Broker Non-Votes
	16,718,137				4,971,378				800,482				29,382,396

	ANAVEX LIFE SCIENCES CORP.

	By:	/s/ Christopher Missling
		Name: Christopher Missling, PhD Title: Chief Executive Officer

~~Item~~Date: ~~9.01.~~July ~~Financial~~3, ~~Statements and Exhibits.~~2025

(d) Exhibits.

EXHIBIT NO.	DESCRIPTION	LOCATION
10.1	Amendment No. 1 to Anavex Life Sciences Corp. 2022 Omnibus Incentive Plan, as approved by the Company’s stockholders on June 10, 2025	Filed Herewith
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ANAVEX LIFE SCIENCES CORP.
	/s/ Christopher Missling
	Name: Christopher Missling, PhD
	Title: Chief Executive Officer
Date: June 13, 2025

Filing Compare · ANAVEX LIFE SCIENCES CORP.